Daniel Sitar - BioMark Diagnostics Principal Advisor
| BMKDF Stock | USD 0.15 0.01 6.25% |
Insider
Daniel Sitar is Principal Advisor of BioMark Diagnostics
| Phone | 604 370 0779 |
| Web | https://www.biomarkdiagnostics.com |
BioMark Diagnostics Management Efficiency
The company has return on total asset (ROA) of (1.4493) % which means that it has lost $1.4493 on every $100 spent on assets. This is way below average. BioMark Diagnostics' management efficiency ratios could be used to measure how well BioMark Diagnostics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Gary Pestano | Biodesix | 57 | |
| Keith Meadors | Precipio | N/A | |
| Andrew Macan | Neuronetics | 51 | |
| David Noble | Star Equity Holdings | 54 | |
| Xavier MS | bioAffinity Technologies Warran | 54 | |
| Matthew Molchan | Star Equity Holdings | 57 | |
| Matthew Gage | Precipio | 57 | |
| BBus CA | Intelligent Bio Solutions | 60 | |
| Claire Sears | Neuronetics | N/A | |
| BSRT MPH | RadNet Inc | N/A | |
| Ahmed Sabet | Precipio | 38 | |
| Dr III | Biodesix | 53 | |
| Maria JD | bioAffinity Technologies Warran | 68 | |
| Matt Stauffer | Biodesix | N/A | |
| Bob Halbert | Star Equity Holdings | N/A | |
| Jeffrey Bojar | Biodesix | N/A | |
| Ranjan Jayanathan | RadNet Inc | 68 | |
| Ruth VilligerWilson | RadNet Inc | 60 | |
| Heinrich Rder | Biodesix | N/A | |
| Miri ChikoRadomski | Precipio | N/A | |
| Kara Thornton | Neuronetics | N/A | |
Management Performance
| Return On Asset | -1.45 |
BioMark Diagnostics Leadership Team
Elected by the shareholders, the BioMark Diagnostics' board of directors comprises two types of representatives: BioMark Diagnostics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BioMark. The board's role is to monitor BioMark Diagnostics' management team and ensure that shareholders' interests are well served. BioMark Diagnostics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BioMark Diagnostics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Daniel Sitar, Principal Advisor | ||
| Guoyu MBA, Chief Officer | ||
| Jeff Haince, GM Officer | ||
| Neal Kaplan, CFO of US |
BioMark Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is BioMark Diagnostics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -1.45 | |||
| Operating Margin | (15.72) % | |||
| Current Valuation | 12.8 M | |||
| Shares Outstanding | 83.29 M | |||
| Shares Owned By Insiders | 54.77 % | |||
| Price To Earning | (8.80) X | |||
| Price To Sales | 105.81 X | |||
| Revenue | 43.93 K | |||
| Gross Profit | 43.93 K | |||
| EBITDA | (1.22 M) |
Currently Active Assets on Macroaxis
Other Information on Investing in BioMark Pink Sheet
BioMark Diagnostics financial ratios help investors to determine whether BioMark Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BioMark with respect to the benefits of owning BioMark Diagnostics security.